Author:
Nakajo Ikumi,Inoue Hiroshi,Inaba Masaki,Oikawa Keishi,Katashima Masataka,Sawamoto Taiji,Kurumatani Hajimu,Shiramoto Masanari
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference16 articles.
1. Frumkin LR. The pharmacological treatment of pulmonary arterial hypertension. Pharmacol Rev. 2012;64:583–620.
2. Kunieda T, Nakanishi N, Matsubara H, Ohe T, Okano Y, Kondo H, Nishimura M, Shirato K, Tanabe N, Homma S, Yoshida S, Inokuma S, Kodama M, Koike T, Hishida H. Effects of long-acting beraprost sodium (TRK-100STP) in Japanese patients with pulmonary arterial hypertension. Int Heart J. 2009;50:513–29.
3. Sato N, Kaneko M, Tamura M, Kurumatani H. The prostacyclin analog beraprost sodium ameliorates characteristics of metabolic syndrome in obese Zucker (fatty) rats. Diabetes. 2010;59:1092–100.
4. Takenaka M, Machida N, Ida N, Satoh N, Kurumatani H, Yamane Y. Effect of beraprost sodium (BPS) in a new rat partial unilateral ureteral obstruction model. Prostaglandins Leukot Essent Fatty Acids. 2009;80:263–7.
5. Itoh Y, Nakai A, Kakizawa H, Makino M, Fujiwara K, Kobayashi T, Kato T, Nagata M, Oda N, Katsumata H, Nagasaka A, Itoh M. Alteration of endothelin-1 concentration in STZ-induced diabetic rat nephropathy. Effects of a PGI(2) derivative. Horm Res. 2001;56:165–71.